Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Current Challenges in Inflammatory Bowel Diseases
share announcement

Current Challenges in Inflammatory Bowel Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 859

Special Issue Editor

Dr. Wesley M. Raup-Konsavage

E-Mail Website
Guest Editor
Department of Pharmacology, Penn State College of Medicine, 500 University Dr, Hershey, PA 17033, USA
Interests: inflammatory bowel disease; pain; cannabinoids

Special Issue Information

Dear Colleagues,

The multifactorial etiologies of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), contribute to the difficulties in developing effective treatments. IBD is caused by immunological dysregulation, environmental triggers, and a genetic predisposition, and is also characterized by persistent, recurrent gastrointestinal tract inflammation.

Even with the development novel medications, including immunomodulators, managing and treating IBD still presents many difficulties, particularly due to immunogenicity and variable responsiveness in patients. The variability in disease presentation and development is a significant challenge that makes early diagnosis and individualized treatment more difficult. The intrusive nature of current diagnostic methods, such as endoscopy and imaging, may make it difficult to forecast the severity of the disease or its complications, such as strictures, fistulas, or colorectal cancer. Disparities in care are made worse by the cost of these treatments.

IBD can also lead to increased risk of anxiety, depression, and a lower quality of life. Furthermore, progress toward preventative measures is hampered by a lack of clarity regarding the precise impact of environmental variables and gut bacteria. In this Special Issue, we invite authors to contribute studies around the mechanism of IBD, novel treatments, improving quality of life, and related topics.

Dr. Wesley M. Raup-Konsavage
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ulcerative colitis
  • Chron’s disease
  • inflammatory bowel disease
  • colitis-associated cancer
  • novel pharmaceutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2034 KiB  
Article
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
by Ali Atay, Yavuz Cagir, Mucahit Ergul, Oguz Ozturk, Muhammed Bahaddin Durak and Ilhami Yuksel
J. Clin. Med. 2025, 14(4), 1228; https://doi.org/10.3390/jcm14041228 - 13 Feb 2025
Viewed by 682
Abstract
Background/Objectives: Dose escalation has been commonly used to achieve and maintain response. We aimed to compare the outcomes of adalimumab or infliximab dose escalation in inflammatory bowel disease (IBD) patients. Methods: Treatment persistence (TP) and predictive factors for remission-free treatment discontinuation (r-fTD) were [...] Read more.
Background/Objectives: Dose escalation has been commonly used to achieve and maintain response. We aimed to compare the outcomes of adalimumab or infliximab dose escalation in inflammatory bowel disease (IBD) patients. Methods: Treatment persistence (TP) and predictive factors for remission-free treatment discontinuation (r-fTD) were evaluated in patients treated with adalimumab or infliximab dose escalation between 2019 and 2024. Results: Dose escalation was identified in 142 patients treated with adalimumab (UC: 23.9%; CD: 76.1%) and in 126 patients treated with infliximab (UC: 23.8%; CD: 76.2%). The TP rate was significantly lower in the adalimumab group (35.2%) than the infliximab group (53.2%) (p = 0.003). The survival analysis showed that drug persistence was lower in the adalimumab group compared with the infliximab group (mean time: 74.3 vs. 99.5 months, p < 0.001). TP rates showed no significant differences between UC and CD for both adalimumab (mean time UC: 64.7 months vs. CD: 76.2 months, p = 0.403) and infliximab (mean time UC: 80.3 months and CD: 102.6 months, p = 0.151). The r-fTD rates were significantly higher in the adalimumab group (62.7%) than the infliximab group (39.7%) (p < 0.001). Primary lack of response and secondary loss of response (sLOR) rates were both higher in the adalimumab group (7.7% and 51.4%) than the infliximab group (1.6% and 28.6%). However, serious adverse events were lower in the adalimumab group (2.1%) than the infliximab group (7.9%) (p = 0.027). Conclusions: Infliximab dose escalation was more effective than adalimumab in both UC and CD patients. Regarding the side effect profile, adalimumab dose escalation was found to be safer compared with infliximab. Full article
(This article belongs to the Special Issue Current Challenges in Inflammatory Bowel Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop